Mesoblast (MESO) Stock: Buy, Sell, or Hold?
MESO - Mesoblast Limited American Depositary Shares
$12.83
0.42 (3.38%)
▲
5d:
-6.96%
30d:
-19.41%
90d:
-20.21%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Sep 04, 2026
0d
Get Alerted When MESO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MESO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MESO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MESO is currently trading at $12.83, which is considered oversold relative to its 30-day fair value range of $13.68 to $15.31. From a valuation perspective, the stock is trading at a discount (Forward PE: -213.8) compared to its historical average (206.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MESO is showing sideways momentum. Immediate support is located at $11.89, while resistance sits at $14.47. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: MESO scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $37.00 (+188.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MESO is showing sideways momentum. Immediate support is located at $11.89, while resistance sits at $14.47. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: MESO scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $37.00 (+188.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.68 -
$15.31
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 188.4% below Wall St target ($37.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.68 -
$15.31
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$11.89
Resistance Level
$14.47
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-213.83
Wall Street Target
$37.00
(+188.4%)
Revenue Growth (YoY)
390.7%
Profit Margin
-47.8%
PE vs Historical
-213.8 vs 206.7
CHEAP
Share & Embed Analysis
Last updated: October 22, 2026 9:30 AM ET
Data refreshes hourly during market hours. Next update: 10:30 AM
Data refreshes hourly during market hours. Next update: 10:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MESO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 60 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 62 BUY |
